Preimplantation genetic diagnosis is used to test aneuploidy in the cases of low prognosis in patients opting for in vitro fertilization. It is also instrumental in detection of hereditary single gene disorders, X linked diseases and recently, also for diagnosis of late onset diseases.
Statistics:
The global preimplantation genetic diagnosis market is estimated to account for US$ 53.5 Mn in terms of value in 2020 and is expected to reach US$ 81.6 Mn by the end of 2027.
Global Preimplantation Genetic Diagnosis Market: Drivers
Increasing incidences of genetic diseases is expected to propel growth of the global preimplantation genetic diagnosis market over the forecast period. For instance, according to the study, ‘Estimating Nationwide Prevalence of Live Births with Down Syndrome and Their Medical Expenditures in Korea’, published in Journal of Korean Medical Science in August 2019, the prevalence of live births with Down’s syndrome was 5.03 per 10,000 births between 2007 and 2016.
Moreover, increasing number of fertility centers is also expected to aid in growth of the global preimplantation genetic diagnosis market. For instance, in November 2018, Oregon Reproductive Medicine, a fertility center, started its new clinic in Tigard, Oregon called ORM South.
Statistics:
Chromosomal Abnormalities held dominant position in the global preimplantation genetic diagnosis market in 2019, accounting for 20.1% share in terms of value, followed by X-linked diseases and Aneuploidy, respectively.
Figure 1. Global Preimplantation Genetic Diagnosis Market Share (%), by Value, by Type, 2019
Global Preimplantation Genetic Diagnosis Market: Restraints
Non-availability of embryos for transfer is expected to hinder growth of the global preimplantation genetic diagnosis market. In almost one third of couples opting for preimplantation genetic diagnosis cycles, the result is that there is absence of normal transferrable embryos. This could be owing to the reason that sometimes women may show poor response to the given ovarian stimulation and as a result lesser eggs are produces. In other cases, despite there is an availability of a fair quantity of embryos, their chromosomal value is found to be consistently abnormal.
Moreover, couples who fail in previous IVF of preimplantation genetic diagnosis cycles have very low chances of future success. Such disadvantages further holdback growth of the global preimplantation genetic diagnosis market.
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2019 | Market Size in 2020: | US$ 53.5 Mn |
Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
Forecast Period 2020 to 2027 CAGR: | 6.2% | 2027 Value Projection: | US$ 81.6 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., and Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Global Preimplantation Genetic Diagnosis Market: Opportunities
Application of preimplantation genetic diagnosis in the field of oncology is expected to offer lucrative growth opportunities for players in the global preimplantation genetic diagnosis market. Preimplantation genetic diagnosis has the potential of reducing the chances of conceiving a cancer affected pregnancy. It can help in determination of the gender of the embryo and further only the genetically fit embryos will be implanted and a healthy pregnancy can thus be conceived.
Moreover, further development in DNA technology will improve accuracy in preimplantation genetic diagnosis, thereby aiding in growth of the market.
The global preimplantation genetic diagnosis market was valued at US$ 50.3 Mn in 2019 and is forecast to reach a value of US$ 81.6 Mn by 2027 at a CAGR of 6.2% between 2020 and 2027.
Figure 2. Global Preimplantation Genetic Diagnosis Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
Major players in the global preimplantation genetic diagnosis market are focused on launching new products to expand their product portfolio. For instance, in December 2018, Agilent Technologies Inc. introduced OnePGT, a genome-wide, next-generation sequencing (NGS) solution for preimplantation genetic testing.
Moreover, increasing network of fertility centers is expected to aid in growth of the global preimplantation genetic diagnosis market. For instance, in October 2018, Prelude Fertility partnered with NYU Langone Health to establish NYU Langone Fertility Center (Fertility Center).
Global Preimplantation Genetic Diagnosis Market: Competitive Landscape
Major players operating in the global preimplantation genetic diagnosis include, Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.
Global Preimplantation Genetic Diagnosis Market: Key Developments
Major players in the global preimplantation genetic diagnosis market are focused on adopting partnership and collaboration strategies to enhance their market share. For instance, in July 2020, Thermo Fisher Scientific partnered with First Genetics JCS, a manufacturer of diagnostic equipment and IVD kits intended to advance molecular genetic technologies into clinical practice, for commercialization of next-generation sequencing (NGS)–based diagnostics in Russia.
Preimplantation genetic diagnosis (PGD) is the genetic profiling of the pre implantable embryos and oocytes before their implantation. The preimplantation genetic diagnosis is similar to that of the parental diagnosis in case of screening for a particular genetic disease. The PGD is advantageous in a way that helps to avoid selective pregnancy termination by the development and growth of the healthy fetus. PGD serves as an addendum to assisted reproductive technology. The preimplantation genetic diagnosis is required in vitro fertilization, in order to obtain oocytes from the embryos for the genetic evaluation of the diseased or disease-free conditions. In simpler terms, the preimplantation genetic diagnosis is a technique that is used to identify embryos at risk.
Restraints of the Global Preimplantation Genetic Diagnosis Market
Major factors hampering the growth of the preimplantation genetic diagnosis market during the forecast period constitutes of non-availability of embryos for transfer.
Key features of the study:
Detailed Segmentation
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients